Mendelian randomization: Where are we now and where are we going?

International Journal of Epidemiology

Volumn 44, Issue 2, 2015, Pages 379-388

  Burgess, Stephen ^a,b,c   Timpson, Nicholas J ^b   Ebrahim, Shah ^d   Smith, George Davey ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c HOMERTON COLLEGE   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

DNA METHYLATION; DRUG TARGETING; EDITORIAL; EPIGENETICS; GENETIC ASSOCIATION; GENETIC VARIABILITY; MENDELIAN RANDOMIZATION ANALYSIS; METHODOLOGY; PHENOTYPE; PRIORITY JOURNAL; PUBLICATION; CAUSALITY; CLASSIFICATION; EPIDEMIOLOGY; FORECASTING; GENOME-WIDE ASSOCIATION STUDY; HUMAN; METABOLOMICS; RANDOMIZATION; SAMPLE SIZE; TRENDS;

CAUSALITY; CLASSIFICATION; EPIDEMIOLOGIC RESEARCH DESIGN; FORECASTING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; METABOLOMICS; PHENOTYPE; RANDOM ALLOCATION; SAMPLE SIZE;

EID: 84936768023     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyv108     Document Type: Editorial

References (118)

1. Davey Smith G. Capitalizing on Mendelian randomization to assess the effects of treatments. J R Soc Med 2007;100: 432-35.
2. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
3. C-Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011;342:d548.
4. Clarke R, Bennett DA, Parish S et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 2012;9: e1001177.
5. Benn M, Tybjærg-Hansen A, McCarthy MI, Jensen GB, Grande P, Nordestgaard BG. Nonfasting glucose, ischemic heart disease, and myocardial infarction: a mendelian randomization study. J Am Coll Cardiol 2012;59:2356-65.
6. McArdle PF, Whitcomb BW, Tanner K, Mitchell BD, Shuldiner AR, Parsa A. Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference. BMC Cardiovasc Disord 2012;12:16.
7. Benn M, Tybjærg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG. Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 2011;103:508-19.
8. Trummer O, Pilz S, Hoffmann M et al. Vitamin D levels, vitamin D insufficiency genotypes and mortality: A Mendelian randomization study. Bone 2012;50:S108-09.
9. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 2012;32:1732-41.
10. Pfister R, Sharp S, Luben R et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med 2011; 8:e1001112.
11. Nordestgaard BG, Palmer TM, Benn M et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a mendelian randomisation approach. PLoS Med 2012;9:e1001212.
12. Pfister R, Barnes D, Luben R et al. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. Diabetologia 2011;54:2561-69.
13. Wang Y, Zhang Y, Zhang J et al. Association of a functional single-nucleotide polymorphism in the ALDH2 gene with essential hypertension depends on drinking behavior in a Chinese Han population. J Hum Hypertens 2013;27:181-86.
14. Bjørngaard JH, Gunnell D, Elvestad MB et al. The causal role of smoking on anxiety and depression-A Mendelian Randomization analysis of the HUNT study. Psychol Med 2013;43:711-19.
15. Lewis SJ, Araya R, Davey Smith G et al. Smoking is associated with, but does not cause, depressed mood in pregnancy-a Mendelian randomization study. PLoS One 2011;6:e21689.
16. Drogan D, Sheldrick AJ, Schütze Met al. Alcohol consumption, genetic variants in alcohol deydrogenases, and risk of cardiovascular diseases: a prospective study and meta-analysis. PLoS One 2012;7:e32176.
17. Scott JAG, Berkley JA, Mwangi I et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011;378:1316-23.
18. Kang H, Kreuels B, Adjei O, Krumkamp R, May J, Small DS. The causal effect of malaria on stunting: a Mendelian randomization and matching approach. Int J Epidemiol 2013;42: 1390-98.
19. The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R Mendelian randomization) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012;379:1214-24.
20. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012;379:1205-13.
21. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80.
22. Angrist JD, Krueger AB. Instrumental variables and the search for identification: from supply and demand to natural experiments. J Econ Perspect 2001;15:69-85.
23. von Hinke Kessler Scholder S, Davey Smith G, Lawlor DA, Propper C, Windmeijer F. Mendelian randomization: the use of genes in instrumental variable analyses. Health Econ 2011;20: 893-96.
24. von Hinke Kessler Scholder S, Davey Smith G, Lawlor DA, Propper C, Windmeijer F. The effect of fat mass on educational attainment: examining the sensitivity to different identification strategies. Econ Hum Biol 2012;10:405-18.
25. Davey Smith G, Lawlor DA, Harbord R, Timpson NJ, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. PLoS Med 2008;4:1985-92.
26. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res 2007;16:309-30.
27. Lawlor DA, Harbord RM, Sterne JAC, Timpson NJ, Davey Smith G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27:1133-63.
28. Davey Smith G, Timpson N, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med 2008;12:524-41.
29. Palmer TM, Lawlor DA, Harbord RM et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2011;21: 223-42.
30. Palmer TM, Sterne JAC, Harbord RM et al. Instrumental variable estimation of causal risk ratios and causal odds ratios in mendelian randomization analyses. Am J Epidemiol 2011;173: 1392-403.
31. Timpson NJ, Sayers A, Davey Smith G, Tobias JH. How does body fat influence bone mass in childhood? a mendelian randomisation approach. J Bone Miner Res 2009:24: 522-33.
32. Timpson N, Harbord R, Davey Smith G, Zacho J, Tybaerg-Hansen A, Nordestgaard BG. Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using FTO/MC4R genotype. Hypertension 2009; 54:84-90.
33. Timpson NJ, Nordestgaard BG, Harbord RM et al. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes 2011;35:300-08.
34. Welsh P, Polisecki E, Robertson M et al. Unravelling the directional link between adiposity and inflammation: a bidirectional Mendelian randomisation approach. J Clin Endocrinol Metab 2009;95:93-99.
35. Burgess S, Daniel RM, Butterworth AS, Thompson SG. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol 2015;44:484-95.
36. Burgess S, Davies NM, Thompson SG; EPIC-Inter Act Consortium. Instrumental variable analysis with a nonlinear exposure-outcome relationship. Epidemiology 2014;25: 877-85.
37. Silverwood RJ, Holmes MV, Dale CE et al. Testing for nonlinear causal effects using a binary genotype in a Mendelian randomization study: application to alcohol and cardiovascular traits. Int J Epidemiol 2014;43:1781-90.
38. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol 2015;181:251-60.
39. Burgess S, Freitag DF, Khan H, Gorman DN, Thompson SG. Using multivariable mendelian randomization to disentangle the causal effects of lipid fractions. PLoS One 2014; 9:e108891.
40. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: A 2 × 2 factorial mendelian randomization study. J Am Coll Cardiol 2015;65:1552-61.
41. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44: 512-25.
42. Smith JG, Luk K, Schulz CA et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA 2014;312: 1764-71.
43. Freathy RM, Kazeem GR, Morris RW et al. Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts with smoking status to influence body mass index. Int J Epidemiol 2011;40: 1617-28.
44. Davey Smith G. Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health. Genes Nutr 2011;6:27-43.
45. Davey Smith G. Mendelian randomization for strengthening causal inference in observational studies: application to gene by environment interaction. Perspect Psychol Sci 2010;5: 527-45.
46. Relton CL, Davey Smith G. Epigenetic epidemiology of common complex disease: prospects for prediction, prevention and treatment. PLoS Med 2010;7:e1000356.
47. Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease. Int J Epidemiol 2012; 41:161-76.
48. Groom A, Potter C, Swan DC et al. Postnatal growth and DNA methylation are associated with differential gene expression of the TACSTD2 gene and childhood fat mass. Diabetes 2012;61: 391-400.
49. Liang L, Willis-Owen SA, Laprise C et al. An epigenome-wide association study of total serum immunoglobulin E concentration. Nature 2015;520:670-74.
50. Davey Smith G. Random allocation in observational data: how small but robust effects could facilitate hypothesis-free causal inference. Epidemiology 2011;22:460-63.
51. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG; EPIC-Inter Act Consortium. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol 2015, Mar 15. [Epub ahead of print.] PMID: 25773750.
52. CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013;45: 25-33.
53. Freeman G, Schooling CM, Cowling BJ. Power and sample size calculations for Mendelian randomization studies using one genetic instrument. Int J Epidemiol 2013;42:1157-63.
54. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 2011;40: 740-52.
55. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013;178:1177-84.
56. International Consortium for Blood Pressure Genome-Wide Association Studies; Ehret GB, Munroe PB, Rice KM et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478:103-9.
57. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013;37:658-65.
58. Timpson NJ, Walter K, Min JL et al. A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. Nature Commun 2014;5:4871.
59. Ala-Korpela M, Kangas AJ, Soininen P. Quantitative highthroughput metabolomics: a new era in epidemiology and genetics. Genome Med 2012;4:36.
60. Nordstrom A, Lewensohn R. Metabolomics: moving to the clinic. J Neuroiuume Pharmacol 2010;5:4-17.
61. Zhang GF, Sudhukhan S, Tochtrop GP, Brunengraber H. Metabolomics, pathway regulation and pathway discovery. J Biol Chem 2011;286:23631-5.
62. Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell 2012;13: 263-69.
63. Davies MN, Volta M, Pidsley R et al. Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol 2012;13:R43.
64. Wang Q, Kangas AJ, Soininen P et al. Sex hormone-binding globulin associations with circulating lipids and metabolites and the risk for type 2 diabetes: observational and causal effect estimates. Int J Epidemiol 2015;44:623-37.
65. Würtz P, Wang Q, Kangas AJ et al. Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS Med 2014;11:e1001765.
66. Shin SY, Petersen AK, Wahl S et al. Interrogating causal pathways linking genetic variants, small molecule metabolites and circulating lipids. Genome Med 2014;6:25.
67. Kettunen J, Tukiainen T, Sarin A-P et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012;44:269-76.
68. Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-53.
69. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63.
70. Relton CL, Davey Smith G. Is epidemiology ready for epigenetics? Int J Epidemiol 2012;41:5-9.
71. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014;23:R89-98.
72. Chadeau-Hyam M, Athersuch TJ, Keun HC et al. Meetingin-the-middle using metabolic profiling-a strategy for the identification of intermediate biomarkers in cohort studies. Biomarkers. 2011;16:83-88.
73. Holmes E, Loo RL, Stamler J et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008;453:396-400.
74. Shenker NS, Ueland PM, Polidoro S et al. DNA methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology 2013;24:712-16.
75. Tobi EW, Goeman JJ, Monajemi R et al. DNA methylation signatures link prenatal famine exposure to growth and metabolism. Nat Commun 2014;5:5592.
76. Hernandez-Vargas H, Castelino J et al. Exposure to aflatoxin B1 in utero is associated with DNA methylation in white blood cells of infants in The Gambia. Int J Epidemiol 2015;doi:10.1093/ije/dyv027.
77. Glynn RJ. Promises and limitations of mendelian randomization for evaluation of biomarkers. Clin Chem 2010;56:388-90.
78. Ridker PM, Paynter NP, Danik JS, Glynn RJ. Interpretation of Mendelian randomization studies and the search for causal pathways in atherothrombosis: the need for caution. 2010;8: 465-69.
79. Johansen CT, Hegele RA. Mendelian Randomization. Using Mendelian randomization to determine causative factors in cardiovascular disease. J Intern Med 2013;273:44-47.
80. Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European ancestry. Circulation 2010;121:2284-93.
81. Holmes MV, Simon T, Exeter HJ et al. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol 2013;62:1966-76.
82. Stender S, Frikke-Schmidt R, Nordestgaard BG, Grande P, Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. J Intern Med 2013;273:59-68.
83. Palmer TM, Nordestgaard BG, Benn M et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ 2013;347:f4262.
84. Hingorani A, Humphries S. Nature's randomised trials. Lancet 2005;366:1906-08.
85. Mokry JE, Ahmad O, Forgetta V, Thanassoulis G, Richards JB. Mendelian randomisation applied to drug development in cardiovascular disease: a review. J Med Genet 2015;52: 71-79.
86. Zacho J, Tybjaerg A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359: 1897-908.
87. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012;379:1214-24.
88. IL6R Genetics Consortium. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012;379:1205-13.
89. Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014;35:1782-91.
90. Swerdlow DI, Preiss D, Kuchenbaecker KB et al. HMGcoenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351-61.
91. Frayling TM. Statins and type 2 diabetes: genetic studies on target. Lancet 2015;385:310-12.
92. Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.
93. Bots ML, Visseren FL, Evans GW et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370: 153-60.
94. Sofat R, Hingorani AD, Smeeth L et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010;121:52-62.
95. Freitag DF, Butterworth AS, Willeit P et al. for the Interleukin 1 Genetics Consortium. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabet Endocrinol 2015;3: 243-53.
96. Holmes MV, Lange LA, Palmer T, Lanktree MB, North KE, Almoguera B. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet 2014;94:198-208.
97. Nelson CP, Hamby SE, Saleheen D et al. Genetically determined height and coronary artery disease. N Engl J Med 2015; 372:1608-61.
98. Glymour MM, Tchetgen Tchetgen EJ, Robins JM. Credible Mendelian randomization studies: approaches for evaluating the instrumental variable assumptions. Am J Epidemiol 2012; 175:332-39.
99. Rietveld CA, Medland SE, Derringer J et al. GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science 2013;340:1467-71.
100. Ward ME, McMahon G, St Pourcain B et al. Genetic variation associated with differential educational attainment in adults has anticipated associations with school performance in children. PLoS One 2014;9:e100248.
101. Evans DM, Brion MJ, Paternoster L et al. Mining the human phenome using allelic scores that index biological intermediates. PLoS Genet 2013;9:e1003919.
102. Bulik-Sullivan B, Finucane HK, Anttila V et al. An atlas of genetic correlations across human diseases and traits. Bioarxiv 2015. doi: http://dx.doi.org/10.1101/014498.
103. Boef AGD, Dekkers OM, le Cessie S. Mendelian randomisation studies: a review of the approaches used and the quality of reporting. Int J Epidemiol 2015;44:496-511.
104. Winsløw UC, Rode L, Nordestgaard B. High tobacco consumption lowers body weight: a Mendelian randomization study of the Copenhagen General Population study. Int J Epidemiol 2015;44:540-50.
105. Nordestgaard AT, Thomsen M, Nordestgaard BG. Coffee intake and risk of obesity, metabolic syndrome and type 2 diabetes: a Mendelian randomization study. Int J Epidemiol 2015; 44:551-65.
106. Bergholdt HKM, Nordestgaard BG, Varbo A, Ellervik C. Milk intake is not associated with ischemic heart disease in observational of Mendelian randomization analyses in 98 529 Danish adults. Int J Epidemiol 2015;44: 587-603.
107. Wium-Andersen MK, Ørsted DD, Schurmann Tolstrup J, Nordestgaard BG. Increased alcohol consumption as a cause of alcoholism, without similar evidence for depression: A Mendelian randomization study. Int J Epidemiol 2015;44: 526-39.
108. Hägg S, Fall T, Ploner A et al. Adiposity as a cause of cardiovascular disease: a Mendelian randomization study. Int J Epidemiol 2015;44:578-86.
109. Sungin D, Cornelis MC, Divaris K et al. Using genetics to test the causal relationship of total adiposity and periodontitis: Mendelian 5 randomization analyses in the Gene-Lifestyle Interactions and Dental Endpoints (GLIDE) Consortium. Int J Epidemiol 2015;44:638-50.
110. Brøndum-Jacobsen P, Benn M, Afzal S, Nordestgaard BG. No evidence that genetically reduced 25-hydroxyvitamin D is associated with increased risk of ischemic heart disease or myocardial infarction. A Mendelian randomization study. Int J Epidemiol 2015;44:651-61.
111. Zhao J, Jiang, C, Lam TH, Liu B, Cheng KK, Xu L. Genetically predicted testosterone and electrocardiographic QT interval duration in Chinese: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. Int J Epidemiol 2015;44: 613-20.
112. Gong J, Zubair N. Commentary: Mendelian randomization, testosterone, and cardiovascular disease. Int J Epidemiol 2015; 44:621-22.
113. Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, Leon DA. Limits to causal inference based on mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol 2006;163:397-403.
114. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 2008;5:e177.
115. Glymour MM, Tchetgen EJ, Robins JM. Credible Mendelian randomization studies: approaches for evaluating the instrumental variable assumptions. Am J Epidemiol 2012; 175:332-39.
116. VanderWeele T, Tchetgen Tchetgen E, Cornelis M, Kraft P. Methodological challenges in Mendelian randomization. Epidemiology 2014;25:427-35.
117. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization. Int J Epidemiol 2013; 42:1134-44.
118. Richmond RC, Davey Smith G, Ness AR, den Hoed M, MacMahon G, Timpson NJ. Assessing causality in the association between child adiposity and physical activity levels: A Mendelian randomization analysis. PLoS Med 2014;11: e1001618.